- CH₣2.00bn
- CH₣2.13bn
- $1.68bn
- 64
- 33
- 51
- 45
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,765 | 1,699 | 1,357 | 1,464 | 1,681 |
Cost of Revenue | |||||
Gross Profit | 576 | 533 | 398 | 484 | 483 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,607 | 1,560 | 1,723 | 1,375 | 1,630 |
Operating Profit | 158 | 139 | -365 | 88.8 | 51 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 169 | 138 | -369 | 92 | 58.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 127 | 119 | -388 | 99 | -22.6 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 122 | 114 | -392 | 79.4 | 208 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 122 | 114 | -392 | 79.4 | 208 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.81 | 3.71 | -4.29 | 2.57 | 7.33 |
Dividends per Share |